Anti-IL6 nanobody [SAA0798] (STJN000012)
General Information
| Short Description | Alpaca monoclonal nanobody anti-Interleukin-6 is suitable for use in Universaling and ELISA research applications. |
| Applications | Blocking/ELISA |
| Host | Alpaca |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | SAA0798 |
| Isotype | VHH-8His-Cys-tag |
| Conjugation | Unconjugated |
| Concentration | 2.38 mg/mL |
| Purification | Purified by Nickel column. |
| Formulation | 0.01M PBS, pH 7.4. |
| Storage Instruction | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at-20°C 12 months. Store at-80°C long term. |
Target Information
| Gene Symbol | IL6 |
| Gene ID | 3569 |
| Uniprot ID | IL6_HUMAN |
Additional Info
| Post Translational Modifications | N- and O-glycosylated. |
| Function | Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable). IL6 is a potent inducer of the acute phase response. Rapid production of IL6 contributes to host defense during infection and tissue injury, but excessive IL6 synthesis is involved in disease pathology. In the innate immune response, is synthesized by myeloid cells, such as macrophages and dendritic cells, upon recognition of pathogens through toll-like receptors (TLRs) at the site of infection or tissue injury (Probable). In the adaptive immune response, is required for the differentiation of B cells into immunoglobulin-secreting cells. Plays a major role in the differentiation of CD4(+) T cell subsets. Essential factor for the development of T follicular helper (Tfh) cells that are required for the induction of germinal-center formation. Required to drive naive CD4(+) T cells to the Th17 lineage. Also required for proliferation of myeloma cells and the survival of plasmablast cells. Acts as an essential factor in bone homeostasis and on vessels directly or indirectly by induction of VEGF, resulting in increased angiogenesis activity and vascular permeability. Induces, through 'trans-signaling' and synergistically with IL1B and TNF, the production of VEGF. Involved in metabolic controls, is discharged into the bloodstream after muscle contraction increasing lipolysis and improving insulin resistance. 'Trans-signaling' in central nervous system also regulates energy and glucose homeostasis. Mediates, through GLP-1, crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand. Also acts as a myokine (Probable). Plays a protective role during liver injury, being required for maintenance of tissue regeneration. Also has a pivotal role in iron metabolism by regulating HAMP/hepcidin expression upon inflammation or bacterial infection. Through activation of IL6ST-YAP-NOTCH pathway, induces inflammation-induced epithelial regeneration. |
| Protein Name | Interleukin-6Il-6B-Cell Stimulatory Factor 2Bsf-2Ctl Differentiation FactorCdfHybridoma Growth FactorInterferon Beta-2Ifn-Beta-2 |
| Database Links | Reactome: R-HSA-1059683Reactome: R-HSA-110056Reactome: R-HSA-112411Reactome: R-HSA-2559582Reactome: R-HSA-381426Reactome: R-HSA-6783783Reactome: R-HSA-6785807Reactome: R-HSA-8853884Reactome: R-HSA-8957275Reactome: R-HSA-9660821Reactome: R-HSA-9662834 |
| Cellular Localisation | Secreted |
| Alternative Nanobody Names | Anti-Interleukin-6 nanobodyAnti-Il-6 nanobodyAnti-B-Cell Stimulatory Factor 2 nanobodyAnti-Bsf-2 nanobodyAnti-Ctl Differentiation Factor nanobodyAnti-Cdf nanobodyAnti-Hybridoma Growth Factor nanobodyAnti-Interferon Beta-2 nanobodyAnti-Ifn-Beta-2 nanobodyAnti-IL6 nanobodyAnti-IFNB2 nanobody |
Information sourced from Uniprot.org
Citations
Product Review
Frequently Asked Questions
Common questions about Anti-IL6 nanobody [SAA0798] (STJN000012)
This nanobody targets human Interleukin-6 (IL-6), corresponding to UniProt entry P05231. Reactivity has been confirmed for human IL-6 only.
This nanobody has been validated for blocking and ELISA applications. No additional applications have been confirmed by the manufacturer.
This nanobody is supplied in a VHH-8His-Cys-tag format and is unconjugated. The 8xHis tag enables detection or capture via standard anti-His reagents, and the C-terminal cysteine can support site-specific conjugation downstream if required.
This nanobody was purified by nickel affinity column chromatography, consistent with its 8xHis tag format. Purity is greater than 95% as determined by SDS-PAGE.
The product is supplied at 2.38 mg/mL in 0.01M PBS, pH 7.4. For short-term use, it can be stored at 4°C for 1 to 2 weeks; for longer storage, it should be kept at -20°C for up to 12 months or at -80°C for extended periods. Repeated freeze-thaw cycles should be avoided, and a manual defrost freezer is recommended.
No dissociation constant or affinity constant data are provided in the current product documentation. Researchers requiring quantitative binding data should consider performing independent SPR or BLI characterization under their specific assay conditions.
Orders typically arrive within 1 to 2 weeks, and often sooner depending on your location. If your timeline is critical, please contact us before ordering and we can advise on current lead times.
This product is shipped on gel ice packs to maintain integrity during transit. Priority shipping is used as standard to minimise time in transit.
A Certificate of Analysis (CoA) is provided with every order. If you do not receive one, please contact us and we will issue it promptly.